Potential Therapeutic Drugs for Parkinson’s Disease Based on Data Mining and Bioinformatics Analysis

Table 2

Thirty-one drug candidates for differential gene prediction (drug-gene connection table).

Drug	Gene	Interaction types	Approved?	Administration	Approved use	PubMed ID
Citric acid	MDH2	N/A	Yes	Oral administration	Anticoagulation	10592235
Folic acid	MTR	N/A	yes	Oral administration	Trophic nerve
Hydroxocobalamin	MTR	Cofactor	Yes	Oral administration/intravenous drip	Neuroprotection	18565, 1744096, 7599160, 3812589, 9587031
L-glutamate	ASNS, GLUD1, GOT1	N/A	Phase 3	Oral administration	Neuroprotection	17139284, 17016423, 8288265, 17139284, 17016423, 17444813
Metformin hydrochloride	NDUFA10, NDUFA7, NDUFA9, NDUFB5, NDUFS1, NDUFV2	Inhibitor	Yes	Oral administration	Hypoglycemic effect
Methionine	MTR	Product	Yes	Oral administration	Liver protection	17222188, 16618098, 17615995, 16788729, 17052662
Niacinamide	LDHA	N/A	Yes	Oral administration	Cardiac disease, cognitive disorder	10592235, 17139284, 17016423
Pyridoxal phosphate	GOT1, SDS	Activator	Phase 2	Oral administration	Dyskinesia	11340119, 16925884, 12167474, 11888303, 11752352, 14596599, 15155761, 14646100, 16580895, 15689518
Quercetin	ATP5B	N/A	Phase 1	Oral administration	Pain	10592235
Serine	SDS	N/A	Phase 2	Oral administration	Cognitive improvement	4377655, 14688104, 17139284, 17016423, 500557